|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Gene amplification and expression of the neu (c-erbB-2) sequence in human mammary carcinoma.
|
3412743 |
1988 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
Amplification of HER-2 oncogene was analysed in DNAs obtained from 291 primary human mammary carcinomas.
|
2915900 |
1989 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
5 human mammary carcinoma cell lines showed both amplification and overexpression of HER-2/neu.
|
1699198 |
1990 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
We conclude that IHC offers a favorable alternative to either Southern analysis or Western immunoblotting in the assessment of c-erbB-2 gene copy number and expression levels of oncoprotein in human mammary carcinoma.
|
1979342 |
1990 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
BEFREE |
We conclude that P-IHC offers a favorable alternative to Southern analysis in the assessment of c-erbB-2 gene copy number of this oncoprotein in human mammary carcinoma.
|
7905629 |
1993 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma.
|
7846046 |
1995 |
|
Mammary Carcinoma, Human
|
0.370 |
AlteredExpression
|
disease |
BEFREE |
Similar results were obtained when we tested the effects of bcl-xS adenoviral infection on primary normal human mammary epithelial cells and SUM-190 PT cells, (a c-erbB-2 over-expressing human mammary carcinoma cell line) grown on Matrigel.
|
10935511 |
2000 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
|
10897039 |
2000 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
|
10897039 |
2000 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
|
11248153 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
|
11583189 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide.
|
11583189 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
|
11248153 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
|
11970740 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Increased ErbB-2 tyrosine kinase activity, MAPK phosphorylation, and cell proliferation in the prostate cancer cell line LNCaP following treatment by select pesticides.
|
11222871 |
2001 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
|
12006526 |
2002 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
|
12006526 |
2002 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
|
12839951 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer.
|
12839951 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma.
|
12655533 |
2003 |
|
Mammary Carcinoma, Human
|
0.370 |
Therapeutic
|
disease |
CTD_human |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
15581045 |
2004 |
|
Mammary Carcinoma, Human
|
0.370 |
Biomarker
|
disease |
CTD_human |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
|
15581045 |
2004 |